Tillkännagivande • Jun 17
Metalabs Co., Ltd. announced that it has received KRW 6 billion in funding from Meta Pharm Co., Ltd. On June 17, 2026, Metalabs Co., Ltd. closed the transaction. Tillkännagivande • Mar 07
Metalabs Co., Ltd., Annual General Meeting, Mar 27, 2026 Metalabs Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 518, teheran-ro, gangnam-gu, seoul South Korea New Risk • Oct 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩2.5b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩45.3b market cap, or US$31.6m). Tillkännagivande • Jun 05
Metalabs Co., Ltd. (KOSE:A090370) agreed to acquire an additional 50.39% stake in Momolabs Co., Ltd. for KRW 5.8 billion. Metalabs Co., Ltd. (KOSE:A090370) agreed to acquire an additional 50.39% stake in Momolabs Co., Ltd. for KRW 5.8 billion on June 5, 2025. Momolabs had reported Total assets of KRW 1.81 million, total capital of KRW 411.81 million, sales of KRW 11.2 billion and net income of KRW 944.33 million.
The expected completion of the transaction is June 5, 2025. Tillkännagivande • Mar 08
Metalabs Co., Ltd., Annual General Meeting, Mar 28, 2025 Metalabs Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 518, teheran-ro, gangnam-gu, seoul South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩34.5b market cap, or US$24.0m). New Risk • Dec 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩36b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩36b free cash flow). Minor Risk Market cap is less than US$100m (₩30.6b market cap, or US$21.3m). New Risk • Dec 07
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩35b). Less than 3 years of financial data is available. Market cap is less than US$100m (₩31.6b market cap, or US$22.2m). New Risk • Nov 24
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩36b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩36b free cash flow). Minor Risk Market cap is less than US$100m (₩32.7b market cap, or US$23.3m). Tillkännagivande • Aug 07
Metalabs Co., Ltd. (KOSE:A090370) completed the acquisition of 22.77% stake in SMEDI Co., Ltd. (KOSE:A118000) from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 46.8 billion. Metalabs Co., Ltd. (KOSE:A090370) agreed to acquire 22.77% stake in SMEDI Co., Ltd. (KOSE:A118000) from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 49 billion on June 21, 2024. Metalabs will acquire 35.04 million equity shares and 11.11 million preference shares of SMEDI. As of August 5, 2024, the deal value has been revised to KRW 46.8 billion. The equity shares will be acquired at KRW 859 per share and convertible preferred will be acquire at KRW 1,700.82 per share. Metalabs will finance the acquisition from self-funding and asset sales. The expected completion of the transaction is August 5, 2024.
Metalabs Co., Ltd. (KOSE:A090370) completed the acquisition of 22.77% stake in SMEDI Co., Ltd. (KOSE:A118000) from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 46.8 billion on August 5, 2024. Tillkännagivande • Aug 02
Metalabs Co., Ltd. announced that it has received KRW 18.1 billion in funding On August 2, 2024, Metalabs Co., Ltd. closed the transaction. New Risk • Jul 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩42b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩55.3b market cap, or US$40.3m). Tillkännagivande • Jun 22
Metalabs Co., Ltd. (KOSE:A090370) agreed to acquire 29.99% stake in SMEDI Co., Ltd. (KOSE:A118000) from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW49 billion. Metalabs Co., Ltd. (KOSE:A090370) agreed to acquire 29.99% stake in SMEDI Co., Ltd. (KOSE:A118000) from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW49 billion on June 21, 2024. A cash consideration of KRW 49 billion will be paid by Metalabs Co., Ltd. As part of consideration, KRW 49 billion is paid towards common equity of SMEDI Co., Ltd. The expected completion of the transaction is August 5, 2024. New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩78.2b market cap, or US$60.0m). Board Change • Dec 02
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Mar 06
Metalabs Co., Ltd., Annual General Meeting, Mar 30, 2021 Metalabs Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Dec 28
New 90-day low: ₩1,045 The company is down 10.0% from its price of ₩1,165 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 11% over the same period. Tillkännagivande • Dec 19
Lygos CBx and Metalabs Co., Ltd. Partner to Co-Develop and Commercialize Haircare Products Featuring Cannabinoids Lygos, Inc. and Metalabs Co., LTD. announced a partnership to develop haircare and shampoo products featuring Lygos-CBG™ (cannabigerol). CBG is a cannabinoid that has been reported to interact with the endocannabinoid receptors that are involved in hair growth and inflammation.1-3 Metalabs will incorporate its specialty formulations with Lygos-CBG into a new line of haircare and shampoo products designed for a deep cleansing and purifying process that promotes strand resistance while enhancing volume, shine and growth. The Lygos CBx platform enables the production of many cannabinoid compounds for consumer applications in an environmentally safe, sustainable and cost-effective manner. This partnership enables important product formulations that have not been used due to scalability, consistency and cost issues. Lygos CBx’ novel production pathway offers a high-performance, ultra-pure, THC-free, and consistent alternative to agricultural-based cannabinoid production. The two companies will work together to develop a proprietary formulation and conduct safety and efficacy studies. The results of these studies are expected in 2021, prior to the anticipated commercial launch of the new line of haircare and shampoo products. Is New 90 Day High Low • Sep 24
New 90-day low: ₩1,040 The company is down 9.0% from its price of ₩1,140 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period. 